e-learning
resources
Berlin 2001
Sunday 23.09.2001
New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma
Source:
Annual Congress 2001 - New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Session:
New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Session type:
Poster Discussion
Number:
348
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma. Eur Respir J 2001; 16: Suppl. 31, 348
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012
Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis
Source: Eur Respir J 2005; 26: Suppl. 49, 49s
Year: 2005
Improvement of control and quality of life in severe allergic asthmatics patients treated with omalizumab
Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Year: 2008
Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012
The effect of allergic rhinitis on quality of life and sleep quality in asthmatic patients
Source: Eur Respir J 2006; 28: Suppl. 50, 443s
Year: 2006
The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma
Source: Eur Respir J 2002; 20: 1088-1094
Year: 2002
Improving effect of fudosteine on sputum symptoms and health-related quality of life of patients with bronchial asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 115s
Year: 2006
Quality of life in children with asthma associated with allergic rhinitis
Source: Annual Congress 2009 - How viruses, allergic rhinitis and air pollution affect childhood asthma
Year: 2009
Quality of life in patients with asthma or rhinitis
Source: Eur Respir J 2002; 20: Suppl. 38, 120s
Year: 2002
Evaluation of asthma knowledge and quality of life in adult patients with asthma
Source: Annual Congress 2011 - Asthma: improving diagnosis and management for reaching better control
Year: 2011
Patients with asthma and comorbid allergic rhinitis: Is optimal quality of life achievable in real life?
Source: Annual Congress 2011 - Asthma: risk factors and comorbidities
Year: 2011
Assesment of quality of life in patients with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 284s
Year: 2004
Respiratory symptoms are associated with impaired health-related quality of life in subjects with neither asthma nor COPD
Source: Annual Congress 2009 - Risk factors for asthma and pneumonia
Year: 2009
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006
Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
Source: Eur Respir J 2013; 42: 1224-1233
Year: 2013
Omalizumab in severe asthma: real life study
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Monitoring asthma in childhood: symptoms, exacerbations and quality of life
Source: Eur Respir Rev 2015; 24: 187-193
Year: 2015
Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma
Source: International Congress 2017 – Management of asthma in different situations
Year: 2017
Corticosteroid-dependent bronchial asthma: control of symptoms and quality of life
Source: Eur Respir J 2003; 22: Suppl. 45, 283s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept